Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

45.14
-1.0400-2.25%
Post-market: 45.140.00000.00%19:22 EDT
Volume:621.00K
Turnover:28.60M
Market Cap:3.17B
PE:-14.50
High:47.11
Open:46.52
Low:44.92
Close:46.18
Loading ...

Kymera Therapeutics upgraded to Buy from Neutral at BofA

TIPRANKS
·
03 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus

Reuters
·
03 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Lyra Therapeutics, Church & Dwight, Applied Digital

Reuters
·
02 Jun

Citi Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

TIPRANKS
·
02 Jun

Kymera Therapeutics Up Nearly 35%, on Track for Record Percent Increase -- Data Talk

Dow Jones
·
02 Jun

Kymera Therapeutics Shares Jump 36% After Positive Results From Early-Stage Trial of Its Experimental Therapy

THOMSON REUTERS
·
02 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Xilio Therapeutics, Red Rock Resorts, Kymera

Reuters
·
02 Jun

Kymera Therapeutics Inc. Unveils Presentation on Revolutionizing Immunology with Oral Medicines through Targeted Protein Degradation

Reuters
·
02 Jun

BUZZ-Kymera rises after positive early-stage results for experimental drug

Reuters
·
02 Jun

Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster. -- Barrons.com

Dow Jones
·
02 Jun

Kymera Therapeutics Shares Jump About 43% Premarket After Positive Results From Early-Stage Trial of Its Experimental Therapy

THOMSON REUTERS
·
02 Jun

Kymera Therapeutics Unveils Promising Phase 1 Trial Results for KT-621, a First-in-Class Oral STAT6 Degrader

Reuters
·
02 Jun

Kymera Therapeutics Announces Positive First-in-Human Results From Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral Stat6 Degrader

THOMSON REUTERS
·
02 Jun

Kymera Therapeutics Inc - KT-621 Phase 1B Trial Data Expected 4Q25

THOMSON REUTERS
·
02 Jun

Kymera Therapeutics Inc - Phase 2B Trials in Ad and Asthma to Start 4Q25 and 1Q26

THOMSON REUTERS
·
02 Jun

Kymera Therapeutics Inc - KT-621 Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
02 Jun

Cautious Hold Rating for Kymera Therapeutics Amid Anticipation of STAT6 Degrader Data

TIPRANKS
·
02 Jun

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

THOMSON REUTERS
·
31 May

Kymera Therapeutics (KYMR) Initiated with a Buy at Stifel Nicolaus

TIPRANKS
·
26 May

Kymera Therapeutics Inc. COO Jeremy Chadwick Reports Disposal of Common Shares

Reuters
·
24 May